1. Patients assigned to semaglutide reported reduced major adverse cardiovascular events, regardless of heart failure subtype. 2. Benefits were consistent ...
Click here to read this article in JAMA Internal Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer ...
1. A reduced risk of nephrolithiasis was linked with patients with type 2 diabetes (T2D) initiating sodium-glucose cotransporter 2 inhibitor ...
1. In all patients, there was a 44% reduction in risk of colorectal cancer when using GLP-1RAs as compared to ...
1. HbA1c reduction was dose-dependent in the semaglutide group with the greatest change among patients on semaglutide 50 mg. 2. ...
1. The semaglutide 50 mg group saw a 15.1% reduction in body weight at 68 weeks compared to 2.4% in ...
1. In this retrospective cohort study, glucagon-like peptide-1 receptor agonists (GLP1RA) were associated with a lower risk of major adverse ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
